Dynamic clinical pathways are essential to keep pace with rapid advancements in oncology treatments and FDA approvals. Inclusive participation and effective communication are vital for pathway ...

Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction ...

Major operational milestone achieved as Incannex advances late-stage development of IHL-42X, with all clinical sites identified and trial infrastructure activatedMELBOURNE, Australia and NEW YORK, May ...

When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...

Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer? In the article that accompanies ...

Ryan Haumschild, PharmD, MS, MBA, drives an expert discussion focused on challenges associated with clinical pathway utilization in treating patients with HCC. The panel discussion focused on the ...

Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in ...

Edward G. Neilan from NORD discusses critical efforts to speed up therapy development for rare diseases lacking treatments ...

Company Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization ATLANTA, ...